When I first stepped into a cleanroom where CAR T cells were being cultured, I realized something profound, this wasn’t just biotechnology; it was craftsmanship at the cellular level. Watching millions of T cells swirl inside a bioreactor, growing, dividing, and learning to become cancer killers, I understood that the real power of CAR T therapy lies not only in genetic design but in how these cells are nurtured to life.
CAR T-cell therapy has already changed the story for many patients battling blood cancers. The idea itself still feels magical, take a patient’s own immune cells, reprogram them with a chimeric antigen receptor, and send them back into the body to seek and destroy malignant cells. For B-cell cancers, the target is often CD19, a surface protein that marks both healthy and cancerous B cells. But as we’ve learned over time, cancer is clever. Some cells lose CD19 expression, slipping past the immune radar.
At Cellogen, this challenge is what drives our innovation. We’re developing bispecific CAR T cells that target both CD19 and CD20, two defining markers of B-cell malignancies. By enabling our engineered T cells to recognize dual antigens, we reduce the risk of relapse and strengthen tumor eradication. It’s a simple idea with complex biology behind it, and every step, from design to infusion, depends on the unseen science of cell culture and plasmid manufacturing.
"These circular DNA molecules carry the genetic instructions for building the CAR itself: the recognition domain that binds the tumor, the signaling domains that activate killing, and the co-stimulatory elements that keep the T cell alive and alert. A well-designed plasmid ensures that the right CAR is expressed at the right level, minimizing variability and maximizing performance."
When the plasmid meets the T cell in culture, something extraordinary happens. The cell takes in the new instructions, starts expressing its engineered receptor, and transforms from an ordinary immune cell into a targeted assassin. Over days and weeks, it multiplies, millions of copies of the patient’s own biology, now weaponized to destroy cancer. Watching that transformation never gets old. It’s a living reminder that healing can be grown, not just prescribed.
Our work on CD19/CD20 bispecific CAR T cells embodies the evolution of this field. We’re no longer satisfied with one target or one strategy. We’re designing smarter cells, grown in smarter ways, with the help of better genetic tools. The combination of refined plasmid design, precise culture control, and deep understanding of immunobiology is what makes next-generation therapies possible.
What inspires me most is that every vial of CAR T cells carries a story of a patient waiting for hope, of scientists perfecting the invisible details, of a future where living cells themselves become medicine. And in every step of that journey from plasmid to bioreactor, we’re reminded that curing cancer isn’t just about fighting disease. It’s about mastering the biology of life itself.
At Cellogen, we believe that the future of therapy doesn’t lie in what we can manufacture, but in what we can cultivate. Because the cure doesn’t begin in the clinic, it begins in culture.
- CAR T
.jpg)
.png)
